Neuropathologic and morphometric effects of aminoguanidine on rat nerves

Walter O. Arruda, JaNean Engelstad, Peter J Dyck

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aminoguanidine prevents some pathophysiologic changes typical of streptozocin diabetes and, therefore, might be efficacious in prevention or treatment of human diabetic polyneuropathy. In order to evaluate the possible toxicity of aminoguanidine on peripheral nerves, Sprague-Dawley rats received aminoguanidine intraperitoneally in dosages of 0, 50, 100, and 300 mg/kg per day for 3 months. Only rats receiving the highest dosages developed acute and chronic behavioral changes and had decreased weight gain. Minor hepatic dysfunction also was observed in this group. Teased-fiber abnormalities were not significantly more frequent in the highest dosage group than in controls. Likewise, a significant morphometric abnormality was not found for the peroneal nerve. Mild changes were found in the highest dosage group compared to the control group in the sural nerve (increased fiber density, decreased myelin area). We interpret the small morphometric differences for the sural nerve as due to maldevelopment. We found no evidence that aminoguanidine at a high dosage (300 mg/kg per day) caused fiber degeneration or demyelination.

Original languageEnglish (US)
Pages (from-to)80-84
Number of pages5
JournalJournal of the Neurological Sciences
Volume113
Issue number1
DOIs
StatePublished - 1992

Fingerprint

Sural Nerve
Peroneal Nerve
Control Groups
Experimental Diabetes Mellitus
Diabetic Neuropathies
Demyelinating Diseases
Myelin Sheath
Peripheral Nerves
Nerve Fibers
Weight Gain
Sprague Dawley Rats
pimagedine
Liver

Keywords

  • Aminoguanidine
  • Peripheral nerves
  • Toxic effects

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Surgery
  • Neuroscience(all)
  • Developmental Neuroscience
  • Neurology

Cite this

Neuropathologic and morphometric effects of aminoguanidine on rat nerves. / Arruda, Walter O.; Engelstad, JaNean; Dyck, Peter J.

In: Journal of the Neurological Sciences, Vol. 113, No. 1, 1992, p. 80-84.

Research output: Contribution to journalArticle

Arruda, Walter O. ; Engelstad, JaNean ; Dyck, Peter J. / Neuropathologic and morphometric effects of aminoguanidine on rat nerves. In: Journal of the Neurological Sciences. 1992 ; Vol. 113, No. 1. pp. 80-84.
@article{b686be84d6f449cea4c55ef80403a453,
title = "Neuropathologic and morphometric effects of aminoguanidine on rat nerves",
abstract = "Aminoguanidine prevents some pathophysiologic changes typical of streptozocin diabetes and, therefore, might be efficacious in prevention or treatment of human diabetic polyneuropathy. In order to evaluate the possible toxicity of aminoguanidine on peripheral nerves, Sprague-Dawley rats received aminoguanidine intraperitoneally in dosages of 0, 50, 100, and 300 mg/kg per day for 3 months. Only rats receiving the highest dosages developed acute and chronic behavioral changes and had decreased weight gain. Minor hepatic dysfunction also was observed in this group. Teased-fiber abnormalities were not significantly more frequent in the highest dosage group than in controls. Likewise, a significant morphometric abnormality was not found for the peroneal nerve. Mild changes were found in the highest dosage group compared to the control group in the sural nerve (increased fiber density, decreased myelin area). We interpret the small morphometric differences for the sural nerve as due to maldevelopment. We found no evidence that aminoguanidine at a high dosage (300 mg/kg per day) caused fiber degeneration or demyelination.",
keywords = "Aminoguanidine, Peripheral nerves, Toxic effects",
author = "Arruda, {Walter O.} and JaNean Engelstad and Dyck, {Peter J}",
year = "1992",
doi = "10.1016/0022-510X(92)90268-P",
language = "English (US)",
volume = "113",
pages = "80--84",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Neuropathologic and morphometric effects of aminoguanidine on rat nerves

AU - Arruda, Walter O.

AU - Engelstad, JaNean

AU - Dyck, Peter J

PY - 1992

Y1 - 1992

N2 - Aminoguanidine prevents some pathophysiologic changes typical of streptozocin diabetes and, therefore, might be efficacious in prevention or treatment of human diabetic polyneuropathy. In order to evaluate the possible toxicity of aminoguanidine on peripheral nerves, Sprague-Dawley rats received aminoguanidine intraperitoneally in dosages of 0, 50, 100, and 300 mg/kg per day for 3 months. Only rats receiving the highest dosages developed acute and chronic behavioral changes and had decreased weight gain. Minor hepatic dysfunction also was observed in this group. Teased-fiber abnormalities were not significantly more frequent in the highest dosage group than in controls. Likewise, a significant morphometric abnormality was not found for the peroneal nerve. Mild changes were found in the highest dosage group compared to the control group in the sural nerve (increased fiber density, decreased myelin area). We interpret the small morphometric differences for the sural nerve as due to maldevelopment. We found no evidence that aminoguanidine at a high dosage (300 mg/kg per day) caused fiber degeneration or demyelination.

AB - Aminoguanidine prevents some pathophysiologic changes typical of streptozocin diabetes and, therefore, might be efficacious in prevention or treatment of human diabetic polyneuropathy. In order to evaluate the possible toxicity of aminoguanidine on peripheral nerves, Sprague-Dawley rats received aminoguanidine intraperitoneally in dosages of 0, 50, 100, and 300 mg/kg per day for 3 months. Only rats receiving the highest dosages developed acute and chronic behavioral changes and had decreased weight gain. Minor hepatic dysfunction also was observed in this group. Teased-fiber abnormalities were not significantly more frequent in the highest dosage group than in controls. Likewise, a significant morphometric abnormality was not found for the peroneal nerve. Mild changes were found in the highest dosage group compared to the control group in the sural nerve (increased fiber density, decreased myelin area). We interpret the small morphometric differences for the sural nerve as due to maldevelopment. We found no evidence that aminoguanidine at a high dosage (300 mg/kg per day) caused fiber degeneration or demyelination.

KW - Aminoguanidine

KW - Peripheral nerves

KW - Toxic effects

UR - http://www.scopus.com/inward/record.url?scp=0026493669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026493669&partnerID=8YFLogxK

U2 - 10.1016/0022-510X(92)90268-P

DO - 10.1016/0022-510X(92)90268-P

M3 - Article

VL - 113

SP - 80

EP - 84

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1

ER -